NAT10 and breast carcinoma: Pharmacological evaluations in breast cancer (Wu et al., 2018) and hepatocellular carcinoma (Zhang et al., 2019) models demonstrate that NAT10 silencing effectively counteracts doxorubicin-induced EMT, thereby reversing drug-resistant phenotypes in tumor cells.